AMENDED AND RESTATED SECURITY AGREEMENT Dated as of March 13, 2023 among AgeX Therapeutics, Inc. and Each Other Grantor From Time to Time Party Hereto and Juvenescence Limited as Agent and Initial LenderSecurity Agreement • March 15th, 2023 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 15th, 2023 Company Industry JurisdictionAMENDED AND RESTATED SECURITY AGREEMENT, dated as of March 13, 2023, by AgeX Therapeutics, Inc., a Delaware corporation, (the “Borrower”) and each of the other entities that becomes a party hereto, including pursuant to Section 8.6 (together with the Borrower, the “Grantors” and each a “Grantor”), in favor of Juvenescence Limited, a company incorporated in the Isle of Man (the “Initial Lender”), in its capacity as the Lender under the Notes referred to below and as agent for itself and any other lender under the Notes (in such capacity, together with its successors and permitted assigns, “Agent” and the Agent and the Lenders from time to time under the Notes, together with their respective successors and permitted assigns, the “Secured Parties”). This Agreement amends and restates in its entirety that certain Security Agreement, dated as of February 14, 2022, by the Borrower and the Grantors in favor of the Initial Secured Parties.
SECURITY AGREEMENT Dated as of February 14, 2022 among AgeX Therapeutics, Inc. and Each Other Grantor From Time to Time Party Hereto and Juvenescence Limited as Agent and Initial LenderSecurity Agreement • February 15th, 2022 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 15th, 2022 Company Industry JurisdictionSECURITY AGREEMENT, dated as of February 14, 2022, by AgeX Therapeutics, Inc., a Delaware corporation, (the “Borrower”) and each of the other entities that becomes a party hereto, including pursuant to Section 8.6 (together with the Borrower, the “Grantors” and each a “Grantor”), in favor of Juvenescence Limited, a company incorporated in the Isle of Man (the “Initial Lender”), in its capacity as the Lender under the Note referred to below and as agent for itself and any other lender under the Note (in such capacity, together with its successors and permitted assigns, “Agent” and the Agent and the Lenders from time to time under the Note, together with their respective successors and permitted assigns, the “Secured Parties”).